Comparative bioequivalence study of the Linagliptin 5-mg Tablets manufactured by DarmanYab Darou Pharmaceutical Company with Linagliptin brand tablets (Tradjenta®) by Boehringer Ingelheim.

Darmanyab darou pharmaceutical company0 个研究点目标入组 24 人开始时间: 待定最近更新: 2022年8月29日

适应症

试验速览

暂无简介。

•The weight limit of each volunteer should be between 60 and 100 kg.
•All volunteers must be non-smokers.
•They must be healthy in terms of liver, kidney, respiratory system, mental and other general health characteristics that will be assessed.
•Candidates who have consented to the consent form.

•Known hypersensitivity or idiosyncratic reaction to Linagliptin or any ingredients.
•Subjects with BP = 90/60 mm/Hg or BP = 140/90 mm/Hg.
•Regular smoker who smokes more than ten cigarettes daily.
•Taking any medicine during two weeks before dosing.

发起方

Darmanyab darou pharmaceutical company